Aminalon is a trade name of pharmaceutical grade gamma-aminobutyric acid (GABA) supplementation. GABA is the main inhibitory neurotransmitter in the central nervous system. Usually, GABA receptors are the primary target of anxiolytic drugs.
Aminalon does not easily penetrate the blood-brain barrier unlike its derivative, Phenibut. But in the body, GABA is metabolized to succinic semialdehyde which is further oxidized to alpha-ketoglutarate. Some of the α-Ketoglutaric acid is able to reach the central nervous system, where it can be transformed into the GABA.
Aminalon does have nootropic and anticonvulsant effects. The mechanism of action is related to its ability to activate GABA-A and GABA-B receptors. The activation of GABA-A receptors leads to the opening of chloride-permeable ion channels, reducing the activity of the neurons.
Aminalon is able to improve mental performance and consolidation of memory and acts positively on the recovery of motor and speech functions in stroke patients. The drug has mild antihypoxic and anticonvulsant activity. It does increase seizure threshold and decrease the frequency of seizures, without affecting the seizure length significantly.
Because of its moderate hypotensive activity, it can lower down high blood pressure, and alleviate symptoms associated with it, like vertigo or insomnia.
Indications for use are:
- Cerebrovascular disorders and traumatic brain injuries.
- Psychoorganic syndrome.
- Atherosclerotic, hypertonic and alcoholic encephalopathy.
- Cerebral palsy and perinatal brain injuries in kids.
- Delayed development in kids.
- Motion sickness.
Possible side effects include nausea, fever, insomnia, and labile blood pressure.
The dosage recommended by the manufacturer is 0,5-1,25g three times a day. The length of treatment should not be less than 2-3 weeks, while the recommended course length is 2-4 months. The course may be repeated 1-2 times yearly.
For the treatment of motion sickness, Aminalon should be taken in 0,5g dosage twice daily, for 3-4 days prior to travel.